Dihexa vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dihexa
Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | Dihexa | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |